This federal contract award, valued at $527,132.89, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price and has no set-aside designation, indicating open competition.
The award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., also doing business as Amerisourcebergen. The IDC, valued at up to $999,999,999.00, provides a comprehensive global pharmaceutical support vehicle for the DLA Troop Support Medical, with a performance period extending through December 2026. This IDC enables Amerisourcebergen to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.
The current delivery order covers a variety of pharmaceutical products, including medications across multiple therapeutic domains such as diabetes treatments, neurological medications, pain management pharmaceuticals, hormone treatments, antibiotics, and specialized medical supplies. This contract award demonstrates Amerisourcebergen's capacity to efficiently fulfill diverse federal medical supply requirements.